Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4990898 | 0.93 | TAAR1 (0.48) | MTNR1AMTNR1BTAAR1CYP1A2PPARA | |
| SCHEMBL4983819 | 0.90 | PPARA (0.45) | PPARACHRM2CHRM1CHRM3GRIK1 | |
| SCHEMBL4983506 | 0.90 | PTGS2 (0.39) | GRIK1 | |
| SCHEMBL4984871 | 0.87 | PPARG (0.43) | PPARACHRM2CHRM1CHRM3 | |
| SCHEMBL4987223 | 0.86 | MTNR1A (0.48) | MTNR1AMTNR1BTAAR1HDAC1HDAC6 | |
| SCHEMBL4984018 | 0.86 | PPARG (0.45) | TAAR1KMT2AGRIK1 | |
| SCHEMBL4990939 | 0.86 | PPARA (0.53) | TAAR1CYP1A2PPARAMEN1KMT2A | |
| SCHEMBL4989052 | 0.85 | ANPEP (0.44) | TAAR1HDAC6GRIK1 | |
| SCHEMBL4983574 | 0.85 | GRIK1 (0.43) | TAAR1HDAC1HDAC6KMT2AGRIK1 | |
| SCHEMBL4983562 | 0.84 | GRIK1 (0.42) | TAAR1MEN1KMT2AGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | MTNR1A 1012/4885MTNR1B 795/4885TAAR1 1437/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | MTNR1A 967/4885MTNR1B 836/4885TAAR1 1172/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | MTNR1A 934/4885MTNR1B 744/4885TAAR1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.